A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- Sponsors AbbVie
- 28 Sep 2018 Planned End Date changed from 29 Jul 2020 to 5 May 2020.
- 28 Aug 2018 Planned primary completion date changed from 29 Jul 2020 to 27 Aug 2019.
- 18 Oct 2017 New trial record